- ABILIFY Used With Another Antidepressant Can Help Adults Living With
Depression Who Have Failed to Achieve Adequate Symptom Relief -(1)
PRINCETON, N.J. and TOKYO, Nov. 20 /PRNewswire-FirstCall/ --
Bristol-Myers Squibb Company (NYSE: BMY) and Otsuka Pharmaceutical Co.,
Ltd. announced today that the U.S. Food and Drug Administration (FDA)
approved the supplemental New Drug Application for ABILIFY(R)
(aripiprazole) as adjunctive, or add-on, treatment to antidepressant
therapy (ADT) in adults with major depressive disorder (MDD). ABILIFY is
the first medication approved by the FDA as add-on treatment for MDD.
"The approval of this new add-on treatment option is critical for
adults suffering from depression who cannot find sufficient relief for
their symptoms with antidepressants alone," said Madhukar Trivedi, M.D.,
Professor and Chief- Division of Mood Disorders, University of Texas
Southwestern Medical School, Dallas, Texas. "Now physicians have a proven
new option they can add to their patients' antidepressant treatments to
help them feel better and relieve unresolved depressive symptoms."
The approval is based on results from two six-week, double-blind,
randomized, placebo-controlled, multicenter studies (n=743). The results
from both studies demonstrated significant improvement in depressive
symptoms in adult patients with a primary diagnosis of major depressive
disorder who had experienced an inadequate response* to monotherapy with
one or more ADTs in the current episode and then added ABILIFY to their
treatment regimens.
"We are committed to helping those who suffer from depression, one of
the leading causes of disability in the United States and worldwide," said
Elliott Sigal, M.D., Ph.D., Executive Vice President, Chief Scientific
Officer and President, Research and Development, Bristol-Myers Squibb.
"This approval is a reflection of our ongoing commitment to provide
innovative therapies, such as ABILIFY, to help adults living with
depression."
"We are pleased that ABILIFY has achieved this important milestone as
the first medication approved as adjunctive treatment for adults with major
depressive disorder," said Taro Iwamoto, Ph.D., Chief Executive Officer,
President and Chief Operating Officer, Otsuka Pharmaceutical Development
and Commercialization, Inc. "This new add-on treatment option for
depression represents hope for many adults suffering from this debilitating
illness."
Major depressive disorder affects millions of U.S. adults at some point
in their lives.(2) A recent study evaluated different treatment approaches,
including adjunctive medications and switching strategies, in patients with
MDD.(1) The study found that 63 percent of patients did not achieve
adequate relief of depressive symptoms following the initial treatment with
an antidepressant alone.(1) Additionally, the study demonstrated that the
use of adjunctive medications in treatment may be useful to improve
unresolved depressive symptoms.(1)
Clinical Trial Design and Findings
Two six-week, double-blind, randomized, placebo-controlled, multicenter
studies evaluated the efficacy and safety of add-on ABILIFY in adult
patients with a primary diagnosis of major depressive disorder who had
experienced an inadequate response to prior antidepressant therapy (one to
three courses) in the current episode.
After an eight-week prospective treatment phase with one ADT plus
single- blind placebo to confirm inadequate response to ADT, 743
participants entered a six-week randomized treatment phase during which
they continued their ADT plus double-blind adjunctive placebo or adjunctive
ABILIFY. All study participants received one of the commonly prescribed
ADTs, including selective serotonin reuptake inhibitors (SSRIs): Lexapro(R)
(escitalopram), Prozac(R) (fluoxetine), Paxil CR(R) (paroxetine
controlled-release), Zoloft(R) (sertraline); or a serotonin-norepinephrine
reuptake inhibitor (SNRI): Effexor XR(R) (venlafaxine extended release).
The dosage range for adjunctive ABILIFY was 2-20 mg/day (15 mg/day was the
maximum dose for patients receiving ABILIFY as an adjunct to Paxil CR or
Prozac).
The primary efficacy endpoint was the mean change from baseline -- the
end of the prospective treatment phase -- to the end of the randomized
treatment phase in a standard measure called Montgomery-Asberg Depression
Rating Scale (MADRS), a 10-item clinician-rated scale used to assess
depressive symptoms. A reduction in MADRS Total Score represents an
improvement in depressive symptoms. The key secondary endpoint was the
Sheehan Disability Scale (SDS), a three-item self-rated instrument used to
assess the impact of depression on three domains of functioning
(work/school, social life and family life) with each item scored from zero
(not at all) to 10 (extreme). Safety evaluations included incidence of
adverse reactions, discontinuation rate due to adverse reactions and
laboratory measures.
For the primary endpoint, both studies showed that taking ABILIFY plus
an ADT provided superior improvement in depressive symptoms to ADT alone at
study endpoint (week six), as measured by the reduction of the MADRS Total
Scores.(3) For the secondary endpoint, ABILIFY plus an ADT was also
superior to placebo plus ADT in reducing the mean SDS Total Score in one
study.
In these studies, adjunctive ABILIFY demonstrated no clinically
important differences on metabolic parameters, including prolactin, fasting
glucose, HDL, LDL and total cholesterol. The median percent change from
baseline in triglycerides was 5 percent for adjunctive ABILIFY-treated
patients vs 0 percent for adjunctive placebo-treated patients. In the
studies, weight gain greater than or equal to 7 percent increase from
baseline was seen in 5 percent of adult patients treated with adjunctive
ABILIFY and 1 percent of adjunctive placebo-treated patients. The mean
change from baseline in weight was 1.7 kilograms (kg) for adjunctive
ABILIFY and 0.4 kg for adjunctive placebo.
In a pool of two placebo-controlled trials of patients, the rate of
discontinuation due to adverse reactions with the use of adjunctive ABILIFY
compared to placebo plus ADT was 6 percent vs 2 percent, respectively. The
most commonly observed adverse reactions (incidence greater than or equal
to 5 percent and at least twice the incidence of placebo plus ADT)
associated with the use of adjunctive ABILIFY were akathisia (25 percent vs
4 percent), restlessness (12 percent vs 2 percent), insomnia (8 percent vs
2 percent), constipation (5 percent vs 2 percent), fatigue (8 percent vs 4
percent) and blurred vision (6 percent vs 1 percent).
About Major Depressive Disorder
Major depressive disorder is a serious mental illness(4)characterized
by one or more major depressive episodes.(5) Depression affects
approximately 13 to 14 million adults,(2) or about 6.7 percent of the adult
population in a given year,(6) and is one of the most common mental health
disorders.(7) Depression is one of the leading causes of disability in the
U.S.(8) In 2000, the total economic burden of treating depression in the
U.S. was $83.1 billion, with workplace costs, including missed days and
lack of productivity due to illness, accounting for the majority of the
total economic burden (62 percent).(9) Other economic burdens in 2000
included $26.1 billion (31 percent) for treatment costs and $5.4 billion (7
percent) for suicide- related costs.(9)
About ABILIFY
The first and only available dopamine partial agonist, ABILIFY is
indicated as adjunctive treatment to antidepressant therapy in adults with
major depressive disorder.
Initially approved in November 2002, over 12.5 million prescriptions
have been written for ABILIFY in the U.S.(10) through June 2007.
ABILIFY is available by prescription only. ABILIFY Tablets should be
taken once daily with or without food and are available in 2 mg, 5 mg, 10
mg, 15 mg, 20 mg and 30 mg strengths. As adjunctive treatment to
antidepressant therapy in adults with major depressive disorder, ABILIFY
Oral starting dose is 2 mg/day to 5 mg/day with a maximum dose of 15
mg/day. Dose adjustments of up to 5 mg/day should occur gradually, at
intervals of no less than one week.
IMPORTANT SAFETY INFORMATION and INDICATIONS for ABILIFY
INDICATIONS:
-- ABILIFY is indicated for use as an adjunctive treatment to
antidepressants for major depressive disorder in adults.
IMPORTANT SAFETY INFORMATION:
Elderly patients with dementia-related psychosis treated with atypical
antipsychotic drugs are at an increased risk of death compared to placebo.
ABILIFY is not approved for the treatment of patients with dementia-related
psychosis (see Boxed WARNING).
Antidepressants increased the risk compared to placebo of suicidal
thinking and behavior (suicidality) in children, adolescents, and young
adults in short-term studies of major depressive disorder (MDD). Patients
of all ages who are started on antidepressant therapy should be monitored
appropriately and observed closely for clinical worsening, suicidality, or
unusual changes in behavior, especially during the initial few months of
therapy, or at times of dose changes. ABILIFY is not approved for use in
pediatric patients with depression (See Boxed WARNING).
Cerebrovascular adverse events (eg, stroke, transient ischemic attack),
including fatalities, have been reported at an increased incidence in
clinical trials of elderly patients with dementia-related psychosis
treated with ABILIFY
Neuroleptic malignant syndrome (NMS)-As with all antipsychotic
medications, a rare and potentially fatal condition known as NMS has been
reported with ABILIFY. NMS can cause hyperpyrexia, muscle rigidity,
diaphoresis, tachycardia, irregular pulse or blood pressure, cardiac
dysrhythmia, and altered mental status. If signs and symptoms appear,
immediate discontinuation is recommended
Tardive dyskinesia (TD)-The risk of developing TD and the potential for it
to become irreversible may increase as the duration of treatment and the
total cumulative dose increase. Prescribing should be consistent with the
need to minimize TD. If signs and symptoms appear, discontinuation should
be considered since TD may remit, partially or completely
Hyperglycemia and diabetes mellitus-Hyperglycemia, in some cases
associated with ketoacidosis, coma, or death, has been reported in
patients treated with atypical antipsychotics including ABILIFY. Patients
with diabetes should be monitored for worsening of glucose control; those
with risk factors for diabetes should undergo baseline and periodic
fasting blood glucose testing. Patients who develop symptoms of
hyperglycemia should also undergo fasting blood glucose testing. There
have been few reports of hyperglycemia with ABILIFY
ABILIFY may be associated with orthostatic hypotension and should be
used with caution in patients with known cardiovascular disease,
cerebrovascular disease, or conditions which would predispose them to
hypotension.
As with other antipsychotic drugs, ABILIFY should be used with caution
in patients with a history of seizures or with conditions that lower the
seizure threshold.
Like other antipsychotics, ABILIFY may have the potential to impair
judgment, thinking, or motor skills. Patients should not drive or operate
hazardous machinery until they are certain ABILIFY does not affect them
adversely.
Disruption of the body's ability to reduce core body temperature has
been attributed to antipsychotics. Appropriate care is advised for patients
who may exercise strenuously, be exposed to extreme heat, receive
concomitant medication with anticholinergic activity, or be subject to
dehydration.
The possibility of a suicide attempt is inherent in psychotic illnesses
and bipolar disorder, and close supervision of high-risk patients should
accompany drug therapy.
Esophageal dysmotility and aspiration have been associated with
antipsychotic drug use, including ABILIFY; use caution in patients at risk
for aspiration pneumonia.
Physicians should advise patients to avoid alcohol while taking
ABILIFY.
Strong CYP3A4 or CYP2D6 inhibitors increase ABILIFY drug concentrations
when used concomitantly.
CYP3A4 inducers decrease ABILIFY drug concentrations when used
concomitantly.
Commonly observed adverse reactions (greater than or equal to 5 percent
incidence and at least twice the rate of placebo for adjunctive ABILIFY vs
adjunctive placebo, respectively):
-- Adult patients with major depressive disorder: akathisia (25 percent vs
4 percent), restlessness (12 percent vs 2 percent), insomnia (8 percent
vs 2 percent), constipation (5 percent vs 2 percent), fatigue
(8 percent vs 4 percent), and blurred vision (6 percent vs 1 percent).
Please see FULL PRESCRIBING INFORMATION, including Boxed WARNING, for
ABILIFY.
About Bristol-Myers Squibb and Otsuka Pharmaceutical Co., Ltd.
Bristol-Myers Squibb and Otsuka Pharmaceutical Co., Ltd. are
collaborative partners in the development and commercialization of ABILIFY
in the United States and major European countries.
ABILIFY was discovered by Otsuka Pharmaceutical Co., Ltd. Founded in
1964, Otsuka Pharmaceutical Co., Ltd. is a global healthcare company with
the corporate philosophy: "Otsuka - people creating new products for better
health worldwide." Otsuka researches, develops, manufactures and markets
innovative and original products, with a focus on pharmaceutical products
for the treatment of diseases and consumer products for the maintenance of
everyday health. Otsuka is committed to being a corporation that creates
global value, adhering to the high ethical standards required of a company
involved in human health and life, maintaining a dynamic corporate culture,
and working in harmony with local communities and the natural environment.
The Otsuka Pharmaceutical Group comprises 99 companies and employs
approximately 31,000 people in 17 countries and regions worldwide. Otsuka
and its consolidated subsidiaries earned U.S. $7.2 billion in annual
revenues in fiscal 2006.
Bristol-Myers Squibb is a global pharmaceutical and related healthcare
products company whose mission is to extend and enhance human life.
For more information and FULL PRESCRIBING INFORMATION,
including Boxed WARNING, visit: http://www.abilify.com
Visit Bristol-Myers Squibb at: http://www.bms.com
Visit Otsuka Pharmaceutical Co., Ltd. at: http://www.otsuka-global.com
* Inadequate response for prospective treatment was defined as less than
50 percent improvement on the 17-item version of the Hamilton Depression
Rating Scale (HAMD17), minimal HAMD17 score of 14, and a Clinical Global
Impressions Improvement rating of no better than minimal improvement.
References
(1) Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and Longer-Term
Outcomes in Depressed Outpatients Requiring One or Several Treatment
Steps: A STAR*D Report. Am J Psych. 2006;163:1905-1917.
(2) Kessler RC, Berglund P, Demler O, et al. The epidemiology of major
depressive disorder: results from the national comorbidity survey
replication (NCS-R). JAMA. June 18 2003;289(23):3095-3105.
(3) Berman RM, Marcus RN, Swanink R, et al. The Efficacy and Safety of
Aripiprazole as Adjunctive Therapy in Major Depressive Disorder: A
Multicenter, Randomized, Double-Blind, Placebo-Controlled Study. J
Clin Psychiatry. 2007;68:843-853.
(4) National Alliance on Mental Illness (NAMI) Web site. About Mental
Illness: Major Depression. 2006. Accessed August 2007.
(5) Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition,
Text revision. Washington DC, American Psychiatric Association, 2000.
(6) Kessler RC, Chiu WT, Demler OD, Walters EE. Prevalence, severity, and
comorbidity of 12-month DSM-IV disorders in the national comorbidity
survey replication. Arch Gen Psychiatry. 2005;62:617-627.
(7) Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE.
Lifetime Prevalence and Age-of-Onset Distributions of DSM-IV
Disorders in the National Comorbidity Survey Replication. Arch Gen
Psychiatry. 2005;62:593-602.
(8) Michaud CM, McKenna MT, Begg S, et al. The burden of disease and
injury in the United States 1996. Population Health Metrics.
2006;4:11.
(9) Greenberg PE, Kessler RC, Birnbaum HG, et al. The economic burden of
depression in the United States: How did it change between 1990 and
2000? J Clin Psychiatry. 2003;64(12):1465-1475.
(10) IMS Auditrac NGPS: ABILIFY total monthly retail prescriptions: Data
accessed July 2007.
SOURCE Bristol-Myers Squibb Company and Otsuka Pharmaceutical
Co., Ltd.
 back to top
Related links:
http://www.bms.com
http://www.otsuka-global.com http://www.abilify.com
CONTACT:
David M. Rosen, Communications,
+1-609-252-5675, Pager: +1-866-308-4484, david.m.rosen@bms.com,
John Elicker, Investor Relations, +1-212-546-3775,
john.elicker@bms.com, both of Bristol-Myers Squibb Company; Debra
Kaufmann, Otsuka America Pharmaceutical, Inc., +1-240-683-3568,
debra.kaufmann@otsuka.com; Hideki Shirai, Otsuka Pharmaceutical
Co., Ltd., +81-3-6717-1400, siraih@otsuka.jp
|
